← All trials
NCT02690961
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2016
- Primary completion
- Jun 14, 2016
- Completion date
- Jun 14, 2016
- First posted
- Feb 24, 2016
- Last posted
- May 3, 2017
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Chase Sun Pharmaceutical Co., LTDLead sponsor
- People's Liberation Army of ChinaCollaborator
- Tianjin Chase Sun Pharmaceutical Co., LTDStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.